大清生物Datsing品牌怎么样申请店铺

我要投票

大清生物Datsing在医疗器械行业中的票数：583 更新时间：2025-12-14

大清生物Datsing是哪个国家的品牌？「大清生物Datsing」是北京大清生物技术股份有限公司旗下著名品牌。该品牌发源于北京市，由创始人南龙在2001年期间创立，经过多年的不懈努力和高速发展，现已成为行业的标杆品牌。

外推网助力大清生物Datsing品牌出海！将品牌入驻外推网，定制大清生物Datsing品牌推广信息，可以显著提高大清生物Datsing产品曝光，简直是跨境电商爆单神器！目前仅需1000元/年哦~

北京大清生物技术股份有限公司位于中关村科技园核心地区，公司成立于2001年，是由归国留学人员创立的高新技术企业，主要从事生物医学材料、再生医学与组织工程、干细胞与生物治疗产品的研发、生产、销售和服务，是国内较早进行再生医学、组织工程及生物医用材料产品产业化推进的企业之一。2012年底引进北京水木启程创业投资中心作为战略股东，2014年初引进北极光、天津海达创投公司。2006年，大清生物与四川大学华西医院在生物医学材料的研究和产品开发方面达成战略合作伙伴关系。同时依托清华大学生命科学与医学研究院、材料科学与工程研究院、化学工程系以及众多研究机构的技术优势，整合国内外先进技术和资源，在相关技术产业化方面取得多项突破。

大清生物目前有八个产品获得CFDA医疗器械产品注册，分别是：新一代高科技产品可吸收止血膜（大清生物纸）、人造皮肤——基因转染猪皮（贴肤）、同种异体骨修复材料（拜欧金）、同种异体肌腱修复材料（拜欧腱）、生物疝修补片（瑞拜善）、I号牙科种植体、骨修复材料（植骨灵）及牙齿脱敏剂（奥敏清）。目前，公司尚有5个产品在国家指定的临床试验基地开展临床研究或已经完成临床，同时有数个系列产品正在研发中。

大清生物于2003年取得Ⅲ类《医疗器械生产许可证》，2005年通过医疗器械生产企业质量体系考核。2007年通过ISO9001—ISO13485国际质量体系认证。2008年获得国家口腔科材料医疗器械经营许可证。2016年，牙齿脱敏剂产品通过了欧盟CE认证，可吸收止血膜产品通过了CE体系认证。公司在昌平科技园投资建造了4000余平米的先进现代化生产厂房，除生产Ⅱ、Ⅲ类植入医疗器械产品外，还建设了细胞培养室、细胞和支架材料复合产品车间。

为适应企业发展需要，提高企业核心竞争力，公司在中关村医学工程转化中心投资建造了大型研发中心，中心现有研发人员20余名，其中博士2名、硕士10名，高级工程师3名，初步形成了一支多学科有机互补、专业搭配合理的研发队伍。

公司于2012年收购重庆宗申军辉生物技术有限公司（现更名为重庆大清医诚生物技术有限公司）及重庆宗申医达生物技术研发有限公司（现更名为重庆大清医达生物技术有限公司），重庆子公司是专业从事生物医用材料生产的高新技术企业，是典型的“产、学、研”结合体，公司主要产品为基因转染猪皮（贴肤）。

2016年3月收购了北京西格东方医疗电子技术有限公司（现更名为北京大清西格科技有限公司），西格子公司是一家专注数字化口腔产品及服务的供应商，目前公司经销的主要产品有I号种植体、牙齿脱敏剂（奥敏清）、骨粉（拜欧金）等。

2016年9月收购天津中津生物发展有限公司，中津公司是国内较早从事骨活性修复材料生产厂家之一，其主要产品-骨修复材料（植骨灵）为国家专利产品。

大清生物拥有专家、教授、博士和硕士等组成的高科技人才队伍300余人，公司通过建立科学的人力资源考核体系,成立员工持股平台，建立和实施ERP信息管理系统等，树立以人为本的人才观念，打造优秀的企业文化。公司注重员工能力与素质培养，为了提升核心团队的管理能力，2013年、2016年与北京大学光华管理学院合作，特开设EMBA进修一期班、二期班。

Beijing Daqing Biotechnology Co., Ltd. is located in the core area of Zhongguancun Science and technology park. Founded in 2001, it is a high-tech enterprise founded by returned overseas students. It is mainly engaged in the research and development, production, sales and service of biomedical materials, regenerative medicine and tissue engineering, stem cells and biological treatment products. It is the earliest in China to carry out regenerative medicine, tissue engineering and biological treatment One of the enterprises promoting the industrialization of medical material products. At the end of 2012, Beijing Shuimu venture capital center was introduced as the strategic shareholder, and at the beginning of 2014, Beijing Aurora Borealis and Tianjin Haida venture capital company were introduced. In 2006, Daqing biology and West China Hospital of Sichuan University reached a strategic partnership in the research and product development of biomedical materials. At the same time, relying on the technical advantages of the Institute of life science and medicine, the Institute of materials science and engineering, the Department of chemical engineering and many research institutions of Tsinghua University, integrating advanced technologies and resources at home and abroad, we have made many breakthroughs in the industrialization of related technologies. At present, there are eight products of Daqing biology that have obtained CFDA medical device product registration, which are: new generation high-tech product absorbable hemostasis film (Daqing biological paper), artificial skin gene transfected pig skin (skin sticking), allogeneic bone repair material (Bayer gold), allogeneic tendon repair material (Bayer tendon), biological hernia repair sheet (ribeisen), I dental implant , bone repair materials (zhiguling) and tooth desensitizer (aominqing). At present, the company still has 5 products in the national designated clinical trial base to carry out clinical research or have completed clinical research, and several series of products are under development. Daqing biology obtained the class III medical device production license in 2003 and passed the quality system assessment of medical device manufacturers in 2005. In 2007, it passed iso9001-iso13485 international quality system certification. In 2008, it obtained the national stomatological material and medical device business license. In 2016, the tooth desensitizer product passed the EU CE certification, and the absorbable haemostatic film product passed the CE system certification. The company has invested and built more than 4000 square meters of advanced modern production plant in Changping Science and technology park. In addition to producing class II and III implanted medical devices, it has also built cell culture room, cell and scaffold composite product workshop. In order to meet the development needs of the enterprise and improve the core competitiveness of the enterprise, the company has invested and built a large-scale R & D center in Zhongguancun medical engineering transformation center, which has more than 20 R & D personnel, including 2 doctors, 10 masters and 3 senior engineers, and has initially formed a research and development team with multiple disciplines complementing each other organically and reasonable professional collocation. In 2012, the company acquired Chongqing Zongshen Junhui Biotechnology Co., Ltd. (now renamed Chongqing daqingyicheng Biotechnology Co., Ltd.) and Chongqing Zongshen Yida Biotechnology R & D Co., Ltd. (now renamed Chongqing daqingyida Biotechnology Co., Ltd.). Chongqing subsidiary is a high-tech enterprise specializing in the production of biomedical materials and a typical "production, learning and research" The main product of the company is gene transfected pig skin. In March 2016, the company acquired Beijing SiGe Oriental Medical Electronic Technology Co., Ltd. (now renamed Beijing Daqing SiGe Technology Co., Ltd.). Xige company is a supplier focusing on digital oral products and services. At present, the company's main products are no. I implant, tooth desensitizer (aominqing), bone powder (baioujin), etc. In September 2016, Tianjin Zhongjin Biological Development Co., Ltd. was acquired. Zhongjin company is one of the earliest manufacturers of bone active repair materials in China. Its main product bone repair materials (bone graft) is a national patent product. Daqing biology has more than 300 high-tech talents composed of experts, professors, doctors and masters. Through the establishment of a scientific human resources assessment system, the establishment of employee stock holding platform, the establishment and implementation of ERP information management system, the company has established a people-oriented talent concept and built an excellent corporate culture. The company pays attention to the cultivation of employees' ability and quality. In order to improve the management ability of the core team, in 2013 and 2016, it cooperated with Guanghua School of management, Peking University, and specially set up the first and second classes of EMBA advanced studies.

本文链接： https://brand.waitui.com/eddd09692.html 联系电话：请联系客服添加联系邮箱：请联系客服添加